Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/24/2022 01/25/2022 01/26/2022 01/27/2022 01/28/2022 Date
248.85(c) 233.47(c) 224.51(c) 202.9(c) 200.28 Last
288 900 281 535 131 499 314 704 112 397 Volume
-1.03% -6.18% -3.84% -9.63% -1.29% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 199 M - -
Net income 2021 -1 196 M - -
Net cash position 2021 3 536 M - -
P/E ratio 2021 -21,8x
Yield 2021 -
Sales 2022 1 503 M - -
Net income 2022 -1 138 M - -
Net cash position 2022 2 682 M - -
P/E ratio 2022 -21,3x
Yield 2022 -
Capitalization 20 847 M 20 847 M -
EV / Sales 2021 14,4x
EV / Sales 2022 12,1x
Nbr of Employees 7 600
Free-Float 67,7%
More Financials
Company
Beigene Ltd is a biotechnology company in the commercial stage. The Company focuses on research and development (R&D), production and commercialization of innovative drugs. The Company has three products approved for listing, including Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290). The Company also has eight products in clinical stage, including BGB-283, BGB-A333, BGB-A425, BGB-A1217,... 
More about the company
Ratings of BeiGene, Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about BEIGENE, LTD.
05:21aBeiGene Says Chinese Regulator Accepts Supplemental Filing for Leukemia Drug, Grants Br..
MT
05:01aBeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA..
BU
01/25BEIGENE : Announces Acceptance of a Supplemental New Drug Application in China for BRUKINS..
PU
01/25BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/25Immix Biopharma Sees Positive Data for Pancreatic Cancer Treatment in Mouse Trial
DJ
01/25BeiGene Says Global Phase 3 Study of Gastric Cancer Treatment Yields Positive Interim R..
MT
01/24BeiGene's Tislelizumab Boosts Overall Survival In Phase 3 Gastric Cancer Trial
MT
01/24BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination w..
BU
01/24BeiGene, Ltd. Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combina..
CI
01/21BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKIN..
AQ
01/20Health Care Stocks Higher Ahead of Thursday's Close
MT
01/20BeiGene Says China's Medical Products Regulator Accepts Supplemental NDA for Blood Cell..
MT
01/20BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKIN..
BU
01/20BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKIN..
CI
01/19Leap Therapeutics Shares Rise Premarket on Encouraging Study Data
DJ
More news
News in other languages on BEIGENE, LTD.
05:21aBeiGene déclare que l'autorité réglementaire chinoise accepte le dépôt d'un dossier sup..
01/25BeiGene déclare que l'étude mondiale de phase 3 sur le traitement du cancer gastrique d..
01/24BeiGene, Ltd. annonce les résultats positifs de l'essai de phase 3 du tislelizumab en a..
01/20Les actions du secteur de la santé en hausse avant la clôture de jeudi
01/20BeiGene déclare que l'organisme chinois de réglementation des produits médicaux accepte..
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | BGNE | US07725L1026 | MarketScreener
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 202,90 $
Average target price 383,48 $
Spread / Average Target 89,0%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Jane E. Huang Chief Medical Officer-Hematology
Lai Wang Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-25.11%20 847
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-12.95%47 040
BIONTECH SE-40.05%37 325